Effects of Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors

Sponsor
University of Palermo (Other)
Overall Status
Completed
CT.gov ID
NCT03444558
Collaborator
University of Catania (Other)
100
1
2
8.9
11.2

Study Details

Study Description

Brief Summary

Clinical trial about beneficial effects of natural ingredient containing chlorogenic acid and luteolin on liver health and conditions related to liver (such as metabolic syndrome) for general body health.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Natural supplement containing chlorogenic acid and luteolin
  • Other: Placebo (without any active ingredients)
N/A

Detailed Description

This is one randomized, double-blind, placebo-controlled study. The purpose of the present study is to evaluate and/or elucidate the role of the natural supplement, containing chlorogenic acid (10-12%) and luteinyl-7-glucoside (2-4%), on cardio-metabolic risk factors.

The research hypothesis is to evaluate whether natural supplement containing chlorogenic acid and luteolin (Puraltilix, BIONAP SRL, Catania, Italy) may improve several cardio-metabolic parameters in subjects with the metabolic syndrome.

All subjects will be evaluated at baseline and after 6 months of treatment (with natural supplement or placebo).

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
placebo-controlled studyplacebo-controlled study
Masking:
Double (Participant, Investigator)
Masking Description:
double-blind study
Primary Purpose:
Supportive Care
Official Title:
Effect of a Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors in Patients With Metabolic Syndrome
Actual Study Start Date :
Jun 1, 2017
Actual Primary Completion Date :
Feb 28, 2018
Actual Study Completion Date :
Feb 28, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dietary Supplement

50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)

Dietary Supplement: Natural supplement containing chlorogenic acid and luteolin
50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.

Placebo Comparator: Placebo

50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)

Other: Placebo (without any active ingredients)
50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.

Outcome Measures

Primary Outcome Measures

  1. Effect of natural supplement on metabolic parameters including body weight and Body Mass Index (BMI) [Change from baseline to 6 months of the supplementation]

    Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including body weight (kg) and height (m) that will be combined to report BMI in kg/m^2.

  2. Effect of natural supplement on metabolic parameters including waist circumference [Change from baseline to 6 months of the supplementation]

    Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including waist circumference (cm).

  3. Effect of natural supplement on metabolic parameters including plasma lipids [Change from baseline to 6 months of the supplementation]

    Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol HDL-C) (mmol/l), while low-density lipoprotein cholesterol (LDL-C) will be calculated using the Friedewald formula.

  4. Effect of natural supplement on metabolic parameters including glucose metabolism parameters [Change from baseline to 6 months of the supplementation]

    Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma glycemia (mmol/l).

  5. Effect of natural supplement on metabolic parameters including plasma insulinemia and HOMA (homeostatic model assessment) index [Change from baseline to 6 months of the supplementation]

    Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma insulinemia (pmol/L) that with glycemia will be combined to report HOMA index.

Secondary Outcome Measures

  1. Effect of natural supplement on cardio-metabolic parameters including plasma cytokines [Change from baseline to 6 months of the supplementation]

    Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including plasma cytokines (inflammatory markers and adipokines) (pg/ml), that will be assessed using available enzyme-linked immunosorbent assay (ELISA) kits.

  2. Effect of natural supplement on cardio-metabolic parameters including plasma lipoproteins [Change from baseline to 6 months of the supplementation]

    Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including atherogenic lipoproteins as well as the analysis of the full spectrum of lipoprotein subclasses by gel electrophoresis.

  3. Effect of natural supplement on cardio-metabolic parameters including subclinical atherosclerosis [Change from baseline to 6 months of the supplementation]

    Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including subclinical atherosclerosis assessed by carotid intima-media thickness (CIMT) (mm).

  4. Effect of natural supplement on cardio-metabolic parameters including fatty liver index [Change from baseline to 6 months of the supplementation]

    Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including fatty liver index, a noninvasive method used for steatosis detection and quantification.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Men and women aged >18 years with the metabolic syndrome (as defined by the international criteria: Alberti KG, et al. Circulation. 2009; 120: 1640-5);

  • BMI> 25 kg/m^2;

  • Subjects able to swallow whole tablets;

  • Informed consent obtained prior to any study-related activities.

Exclusion Criteria:
  • Pregnancy or willingness to become pregnant;

  • Severe liver dysfunction (ALT >2.5 times upper limit of normal);

  • Severe renal failure (eGFR<60 mL/min/1.73 m2 using the MDRD formula);

  • Severe infections at the discretion of the investigator (such as HIV, HBV and HCV);

  • History or presence of malignant neoplasms within the last 5 years.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital of Palermo Palermo Palrmo Italy 90127

Sponsors and Collaborators

  • University of Palermo
  • University of Catania

Investigators

  • Principal Investigator: Manfredi Rizzo, MD, PhD, University Hospital of Palermo, Italy

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Manfredi Rizzo, MD, PhD, Associate Professor, University of Palermo
ClinicalTrials.gov Identifier:
NCT03444558
Other Study ID Numbers:
  • Natural Supplement
First Posted:
Feb 23, 2018
Last Update Posted:
Oct 24, 2018
Last Verified:
Oct 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Manfredi Rizzo, MD, PhD, Associate Professor, University of Palermo
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 24, 2018